v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates as one operating segment focused on developing and commercializing innovative therapeutics primarily in the U.S. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the chief executive officer, who is the Company's chief operating decision maker, or CODM, in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using income (loss) from operations. Net income (loss) is also a measure that is considered in monitoring budget versus actual results. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit or loss and significant segment expenses for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenues$49,128 $62,472 $102,672 $119,808 
Less:
Direct cost of product and other revenue8,849 6,826 18,883 11,886 
Panion royalty1,575 3,093 3,831 5,658 
Research and development14,059 11,013 28,866 20,767 
Selling, general and administrative28,171 26,555 58,607 52,297 
License855 896 1,562 1,597 
Restructuring1,945 — 1,945 — 
Income (loss) from operations(6,326)14,089 (11,022)27,603 
Other income (expense)
Interest expense(3,071)(6,834)(7,762)(14,604)
Other income(7)(28)(4)185 
Change in fair value of warrant liability566 (6,980)1,022 (6,825)
Income (loss) before income taxes(8,838)247 (17,766)6,359 
Income tax expense(70)— (196)— 
Net income (loss)$(8,908)$247 $(17,962)$6,359